The other PI3K inhibitors are used in the treatment of hematological cancers: idealisib, a PI3Kδ inhibitors [404], copanslisib, the only pan-PI3K inhibitor approved [408], duvelisib, a dual inhibitor of the PI3Kδ and PI3Kγ isoforms [409], and umbralisib, a dual inhibitor of PI3Kδ/casein kinase-1εr (www.fda.gov, (accessed on 20 May 2021) [410]). The gene discussed is PIK3CB; the disease is hematopoietic and lymphoid cell neoplasm.